Progress in the development of preventive and therapeutic vaccines for hepatitis C virus

Published on Jun 1, 2011in Journal of Hepatology18.946
· DOI :10.1016/j.jhep.2010.09.040
Joseph Torresi39
Estimated H-index: 39
(University of Melbourne),
Douglas F. Johnson15
Estimated H-index: 15
(University of Melbourne),
Heiner Wedemeyer73
Estimated H-index: 73
Hepatitis C virus (HCV) is a blood borne disease estimated to chronically infect 3% of the worlds' population causing significant morbidity and mortality. Current medical therapy is curative in approximately 50% of patients. While recent treatment advances of genotype 1 infection using directly acting antiviral agents (DAAs) are encouraging, there is still a need to develop vaccine strategies capable of preventing infection. Moreover, vaccines may also be used in future in combination with DAAs enabling interferon-free treatment regimens. Viral and host specific factors contribute to viral evasion and present important impediments to vaccine development. Both, innate and adaptive immune responses are of major importance for the control of HCV infection. However, HCV has evolved ways of evading the host's immune response in order to establish persistent infection. For example, HCV inhibits intracellular interferon signalling pathways, impairs the activation of dendritic cells, CD8 + and CD4 + T cell responses, induces a state of T-cell exhaustion and selects escape variants with mutations CD8 + T cell epitopes. An effective vaccine will need to produce strong and broadly cross-reactive CD4 + , CD8 + T cell and neutralising antibody (NAb) responses to be successful in preventing or clearing HCV. Vaccines in clinical trials now include recombinant proteins, synthetic peptides, virosome based vaccines, tarmogens, modified vaccinia Ankara based vaccines, and DNA based vaccines. Several preclinical vaccine strategies are also under development and include recombinant adenoviral vaccines, virus like particles, and synthetic peptide vaccines. This paper will review the vaccines strategies employed, their success to date and future directions of vaccine design.
  • References (158)
  • Citations (109)
📖 Papers frequently viewed together
99 Citations
111 Citations
2,206 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1E. BarnesH-Index: 6
#2Antonella FolgoriH-Index: 37
Last. Paul KlenermanH-Index: 88
view all 21 authors...
1 CitationsSource
#1Harel Dahari (UIC: University of Illinois at Chicago)H-Index: 30
#2Stephen M. Feinstone (CBER: Center for Biologics Evaluation and Research)H-Index: 29
Last. Marian E. Major (CBER: Center for Biologics Evaluation and Research)H-Index: 22
view all 3 authors...
Background & Aims Studies in patients and chimpanzees that spontaneously cleared hepatitis C virus (HCV) infections demonstrated that natural immunity to the virus is induced during primary infections and that this immunity can be cross protective. These discoveries led to optimism about prophylactic HCV vaccines, and several studies were performed in chimpanzees, although most included fewer than 6 animals. To draw meaningful conclusions about the efficacy of HCV vaccines in chimpanzees, we per...
74 CitationsSource
#1Ira M. JacobsonH-Index: 20
#2John G. McHutchisonH-Index: 57
Last. David ApelianH-Index: 10
view all 17 authors...
12 CitationsSource
#1Paul Feuerstadt (Albert Einstein College of Medicine)H-Index: 5
#2Ari L. Bunim (Albert Einstein College of Medicine)H-Index: 1
Last. John F. Reinus (Albert Einstein College of Medicine)H-Index: 17
view all 10 authors...
Randomized controlled trials of hepatitis C virus (HCV) therapy with pegylated interferon and ribavirin have demonstrated sustained viral response rates (SVRs) of 54%-63% (efficacy). Treatment results in clinical practice (effectiveness) may not be equivalent. The goal of this study was to assess the effectiveness of HCV treatment with pegylated interferon and ribavirin in a treatment-naive, human immunodeficiency virus (HIV)-negative, United States urban population with many ethnic minority pat...
56 CitationsSource
#1Sophie E. Krieger (UDS: University of Strasbourg)H-Index: 5
#2Mirjam B. Zeisel (UDS: University of Strasbourg)H-Index: 37
Last. Thomas F. Baumert (UDS: University of Strasbourg)H-Index: 62
view all 17 authors...
The tight junction protein claudin-1 (CLDN1) has been shown to be essential for hepatitis C virus (HCV) entry-the first step of viral infection. Due to the lack of neutralizing anti-CLDN1 antibodies, the role of CLDN1 in the viral entry process is poorly understood. In this study, we produced antibodies directed against the human CLDN1 extracellular loops by genetic immunization and used these antibodies to investigate the mechanistic role of CLDN1 for HCV entry in an infectious HCV cell culture...
154 CitationsSource
#1Andri Rauch (University of Bern)H-Index: 36
#2Zoltán Kutalik (Swiss Institute of Bioinformatics)H-Index: 61
Last. Pierre-Yves Bochud (UNIL: University of Lausanne)H-Index: 37
view all 27 authors...
Background & Aims Hepatitis C virus (HCV) induces chronic infection in 50% to 80% of infected persons; approximately 50% of these do not respond to therapy. We performed a genome-wide association study to screen for host genetic determinants of HCV persistence and response to therapy. Methods The analysis included 1362 individuals: 1015 with chronic hepatitis C and 347 who spontaneously cleared the virus (448 were coinfected with human immunodeficiency virus [HIV]). Responses to pegylated interf...
976 CitationsSource
#1Christa Firbas (Medical University of Vienna)H-Index: 19
#2Thomas Boehm (Intercell)H-Index: 2
Last. Christoph Klade (Intercell)H-Index: 19
view all 7 authors...
Abstract Background An effective vaccine would be a significant progress in the management of chronic HCV infections. This study was designed to examine whether different application schedules and injection routes may enhance the immunogenicity of the HCV peptide vaccine IC41. Methods In this randomized trial 54 healthy subjects received either subcutaneous (s.c.) or intradermal (i.d.) vaccinations weekly (16 injections) or every other week (8 injections). One group additionally received imiquim...
40 CitationsSource
#1Henry Radziewicz (Emory University)H-Index: 10
#2Chris C. Ibegbu (Emory University)H-Index: 24
Last. Arash Grakoui (Emory University)H-Index: 29
view all 11 authors...
Costimulatory signals via B7/CD28 family molecules (signal 2) are critical for effective adaptive CD8 + T cell immune responses. In addition to costimulatory signals, B7/CD28 family coinhibitory receptor/ligands that modulate immune responses have been identified. In acute hepatitis C virus (HCV) infection, programmed death receptor 1, an inhibitory receptor in the CD28 family, is highly expressed on virus-specific CD8 + T cells, yet vigorous immune responses often develop. We hypothesized that ...
12 CitationsSource
#1Christoph Neumann-Haefelin (MIT: Massachusetts Institute of Technology)H-Index: 26
#2Jörg TimmH-Index: 16
Last. Robert Thimme (University of Freiburg)H-Index: 54
view all 21 authors...
Human leukocyte antigen B27 (HLA-B27) is associated with protection in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. This protective role is linked to single immunodominant HLA-B27-restricted CD8+ T-cell epitopes in both infections. In order to define the relative contribution of a specific HLA-B27-restricted epitope to the natural course of HCV infection, we compared the biological impact of the highly conserved HCV genotype 1 epitope, for which the protective role h...
46 CitationsSource
#1David L. Thomas (Johns Hopkins University)H-Index: 89
#2Chloe L. Thio (Johns Hopkins University)H-Index: 45
Last. Mary Carrington (MIT: Massachusetts Institute of Technology)H-Index: 46
view all 19 authors...
There are approximately 170 million people infected with hepatitis C virus (HCV) worldwide. About 30% of individuals with persistent HCV infection develop chronic liver disease, with various epidemiological, viral and host factors having been implicated in the differences in HCV clearance or persistence. Here, a single nucleotide polymorphism recently shown to be strongly associated with a difference in response to HCV drug treatment is also shown to be associated with viral clearance.
1,709 CitationsSource
Cited By109
Last. Cristina PeixotoH-Index: 3
view all 7 authors...
Biopharmaceuticals are currently becoming one of the fastest growing segments of the global pharmaceutical industry, being used in practically all branches of medicine from disease treatment to prevention. Virus-like particles (VLP) hold tremendous potential as a vaccine candidate due to their anticipated immunogenicity and safety profile when compared to inactivated or live attenuated viral vaccines. Nevertheless, there are several challenges yet to be solved in the development and manufacturin...
#1Reham M. DawoodH-Index: 3
#2Rehab I Moustafa (Pasteur Institute)H-Index: 3
Last. Mostafa K. El AwadyH-Index: 9
view all 8 authors...
Although DAAs hold promise to significantly reduce rates of chronic HCV infections, its eradication still requires development of an effective vaccine. Prolonged T cell responses and cross neutralizing antibodies are ideal for vaccination against the infection. We aimed to design and synthesize a 6 multi epitope peptide vaccine candidate and provide evidence for production of extended cellular and neutralizing Abs in mice. Six peptides derived from conserved epitopes in E1, E2 (n = 2),NS4B, NS5A...
1 CitationsSource
#1Amir Atapour (Shiraz University of Medical Sciences)H-Index: 2
#2Pooneh Mokaram (Shiraz University of Medical Sciences)H-Index: 13
Last. Navid Nezafat (Shiraz University of Medical Sciences)H-Index: 14
view all 7 authors...
Hepatitis C virus (HCV) infection is a major global issue that leads to serious liver disease such as chronic liver inflammation and hepatocellular carcinoma. At present, no approved vaccine is available for control or treatment of HCV infection. Therefore, the development of an efficient vaccine against HCV is an urgent need. Today, designing an effective vaccine against hepatitis C is one of the outmost propriety for researchers. Fusion protein vaccines containing the immunogen proteins and ad...
2 CitationsSource
#1Makutiro G. Masavuli (University of Adelaide)H-Index: 1
#2Danushka K. Wijesundara (University of Adelaide)H-Index: 10
Last. Branka Grubor-Bauk (University of Adelaide)H-Index: 8
view all 9 authors...
Hepatitis C virus (HCV) persistently infects approximately 71 million people globally. To prevent infection a vaccine which elicits neutralizing antibodies against the virus envelope proteins (E1/E2) which are required for entry into host cells is desirable. DNA vaccines are cost-effective to manufacture globally and despite recent landmark studies highlighting the therapeutic efficacy of DNA vaccines in humans against cervical cancer, DNA vaccines encoding E1/E2 developed thus far are poorly im...
#1Mahmoud El-Bendary (Mansoura University)H-Index: 7
#2Mustafa Neamatallah (Mansoura University)H-Index: 3
Last. Gamal Esmat (Cairo University)H-Index: 33
view all 14 authors...
ABSTRACTBackground: Single nucleotide polymorphisms (SNPs) of Toll-like receptors (TLRs) are linked with functional modification of cytokine responses. In chronic hepatitis C virus (HCV) infection, studies of TLR polymorphisms have primarily targeted receptor pathways implicated in viral immune responses. We hypothesized that one or more variant(s) of TLR3, TLR7 and TLR8 are associated with different outcomes of HCV infection.Materials & methods: A total of 3368 subjects from 850 families were r...
7 CitationsSource
#1Xuan GuoH-Index: 1
#2Jin-yi ZhongH-Index: 1
Last. Jun-wen LiH-Index: 1
view all 3 authors...
In the twenty-seven years since the discovery of hepatitis C virus (HCV) the majority of individuals exposed to HCV establish a persistent infection, which is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. In developed nations, the cure rates of HCV infection could be over 90% with direct-acting antiviral (DAA) regimens, which has made the great progress in global eradication. However, the cost of these treatments is so expensive that the patients in developing...
6 CitationsSource
#1Jihong Liu ClarkeH-Index: 9
#2Lisa ParuchH-Index: 2
Last. Norica Branza-Nichita (Romanian Academy)H-Index: 18
view all 18 authors...
Summary The hepatitis C virus (HCV) is a major etiologic agent for severe liver diseases (e.g., cirrhosis, fibrosis and hepatocellular carcinoma). Approximately 140 million people have chronic HCV infections and about 500,000 die yearly from HCV-related liver pathologies. To date, there is no licenced vaccine available to prevent HCV infection and production of an HCV vaccine remains a major challenge. Here we report the successful production of the HCV E1E2 heterodimer, an important vaccine can...
12 CitationsSource
#1Ashraf A. TabllH-Index: 14
#2Reem El-ShenawyH-Index: 3
Last. Yasmine S. El AbdH-Index: 4
view all 3 authors...
1 CitationsSource
#1Nazrul Islam (Harvard University)H-Index: 9
#2Mel Krajden (UBC: University of British Columbia)H-Index: 44
Last. Naveed Z. Janjua (UBC: University of British Columbia)H-Index: 28
view all 8 authors...
While about a quarter of individuals clear their primary hepatitis C (HCV) infections spontaneously, clearance (spontaneous or treatment-induced) does not confer sterilizing immunity against a future infection. Since successful treatment does not prevent future infections either, an effective vaccine is highly desirable in preventing HCV (re)infection. However, development of an effective vaccine has been complicated by the diversity of HCV genotypes, and complexities in HCV immunological respon...
5 CitationsSource
#1K Borhani (TMU: Tarbiat Modares University)H-Index: 1
#2Taravat Bamdad (TMU: Tarbiat Modares University)H-Index: 13
Last. Tayebeh Hashempour (Shiraz University of Medical Sciences)H-Index: 4
view all 3 authors...
Abstract Hepatitis C virus (HCV) is a blood-borne pathogen which has chronically infected people worldwide. Therefore, it is of utmost importance to design prophylactic and therapeutic vaccine in order to control HCV infection. To date, several researchers have attempted to improve the efficiency of HCV vaccine by using different adjuvants. However, a few studies have focused on the synthetic immunomodulatory drugs as adjuvants for HCV vaccine. Recently, researchers have shown that lenalidomide,...